Research in Your Backyard
In the video featured, learn what thought leaders and experts talked about when they came together to discuss the economic benefits of research and other innovation concepts.
The joint event, hosted by PhRMA and We Work for Health brought together governors, pharma executives, and industry experts to discuss the future of the biotechnology industry in the United States, as well as new innovations that are transforming the way medicine is practiced in the country and around the world.
"Innovation and research are two important components to job creation. Alabama is a leader in medical research, and that supports economic development in our state while also improving lives. The biosciences industry is also a prime area for growth in Accelerate Alabama, our strategic plan for long-term economic development. In 2011, biopharmaceutical research companies in Alabama generated approximately $3.2 billion in economic activity and supported nearly 17,000 jobs." Alabama Gov Rebert Bentley
“The University of Colorado (CU) plays a major role in clinical research. CU is one of a handful of universities that has created four different drugs that have been approved for marketing. CU also has created 18 different drugs currently undergoing clinical trials. Additionally, six CU created drugs have been approved for clinical trials, and 44 drugs are in various stages of pre-clinical trials. CU clinicians are also active in conducting clinical trials. For example, for the 2 month period between January 5, 2012 and March 5, 2012, CU was seeking volunteers for 50 different and newly initiated clinical trials. These clinical related activities address a wide array of human maladies and provide significant economic activity for the State of Colorado.” David N. Allen, Ph.D. University of Colorado Associate Vice President for Technology Transfer
“Clinical trials of new medicines are good not only for patients, but also the state’s economy. About half of those that are underway or have been conducted over the last 13 years are for such challenging diseases as asthma, heart disease, stroke, cancer, diabetes and mental illnesses. These new treatments have the potential to improve the quality of overall patient health care. Clinical trials of new drugs are also a good source of revenue for the state’s university medical schools, local hospitals and clinical research centers.” Eric George, Connnecticut Business & Industry Association
“ With such facilities as M.D. Anderson Cancer Center Orlando, the Cleveland Clinic Florida, the University of Miami and the University of Florida, it’s not at all surprising that biopharmaceutical research companies have taken advantage of the state’s strong biopharmaceutical and life sciences infrastructure to conduct nearly 8,000 clinical trials of new medicines in Florida since 1999, including 3,840 for the most debilitating chronic diseases—cancer, diabetes, heart disease, stroke, asthma and mental illnesses.” Austin Curry, Executive Director, Elder Care Advocacy of Florida
Clinical tests involve three phases and thousands of volunteer patients and are often conducted at multiple sites around the country. In Georgia, biopharmaceutical companies have the luxury of having trials conducted at the states’ well-respected university medical schools, comprehensive cancer centers and clinical trial research centers.
According to U.S. News and World Report, Emory University School of Medical ranked 21st and the Medical College of Georgia ranked 71st among this year’s top 100 research-oriented medical schools in the United States.
“At a time when the state is focused on creating jobs and rebuilding the economy, clinical research and the biopharmaceutical industry have been real bright spots. These companies provide thousands of good-paying jobs, and to the extent they succeed in finding innovative medicines, they make the entire workforce stronger and more productive.” David Miller, President and CEO iBIO (Illinois Biotechnology Industry Organization)
“The 3,266 clinical studies of new medicines conducted in Indiana since 1999 by biopharmaceutical research companies have significantly benefited patients, the state’s economy and the advancement of science and patient care. These companies hire the state’s university medical schools and science centers, hospitals and contract research organizations to conduct the studies, which account for 45 to 75 percent of the average $1.2 billion cost of developing a medicine." Andrew Dahlem, Ph.D, VP, COO, Lilly Research Laboratories
“Iowans may not realize that clinical trials performed right here in Iowa play a very important role in drug development. The ICCR network allows patients to participate actively in clinical trials, which contributes to the development of new drugs and may benefi t all Iowans.” Dr. John M. Weiler CompleWare
“This new report illustrates just how important it is to patients and our state’s economy to have had 568 industry-funded clinical trials of new medicines conducted in the state over the last 13 years. This cutting-edge research has helped to sustain jobs at research centers and hospitals in Portland, Biddeford, Brunswick, Sanford, Scarborough, Rockport, Bangor and other Maine communities." Dana Connors, President, Maine Chamber of Commerce
“Because of its strong research infrastructure, which includes the National Institutes of Health (NIH), Johns Hopkins University and the University of Maryland, Maryland is competitive with some much larger states in its number of clinical trials of new medicines. The nation’s biopharmaceutical research companies have conducted nearly 3,500 new drug tests in the state since 1999 in collaboration with these widely respected institutions and many others." Douglas A. Doerfler, Vice Chairman, MdBio Division, Tech Council of Maryland